Glaukos (GKOS)
(Delayed Data from NYSE)
$119.82 USD
+2.17 (1.84%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $119.74 -0.08 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.82 USD
+2.17 (1.84%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $119.74 -0.08 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
Accuray (ARAY) Incurs Wider Loss in Q2, Misses on Revenue
by Zacks Equity Research
Accuray Inc. (ARAY) reported a loss of 11 cents per share in the second quarter of fiscal 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Align Technology (ALGN) Q4 Earnings and Revenues in Line
by Zacks Equity Research
Align Technology Inc. (ALGN) reported adjusted earnings of 67 cents per share in the fourth quarter of 2016, up 11.6% from 60 cents in the year-ago quarter.
Illumina (ILMN) Beats Q4 Earnings & Revenues, Guides 2017
by Zacks Equity Research
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 85 cents in the fourth quarter of 2016, which exceeded the Zacks Consensus Estimate by 4.9%.
Zimmer Biomet (ZBH) Beats on Q4 Earnings, Knees Improve
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.14, up 2.4% year over year.
Hill-Rom TruSystem 3000 Table Boosts Surgical Solution Suite
by Zacks Equity Research
Hill-Rom Holdings (HRC) recently launched TruSystem 3000 Mobile Operating Table to fulfill hospitals' need to equip operating rooms with quality medical devices at a reasonable cost.
Thermo Fisher (TMO) Q4 Earnings Beat, Organic Sales Flat
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected fourth-quarter and full-year 2016 earnings results.
Abiomed (ABMD) Beats Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Abiomed Inc. (ABMD) reported third-quarter fiscal 2017 earnings of 34 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and surged 47.8% from the year-ago quarter.
C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected
by Zacks Equity Research
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.
Quality Systems (QSII) Beats on Earnings & Revenues in Q3
by Zacks Equity Research
Irvine, CA-based Quality Systems Inc. (QSII) reported third-quarter fiscal 2017 adjusted earnings of 21 cents per share, exceeding the Zacks Consensus Estimate of 18 cents.
Varian Medical (VAR) Misses on Q1 Earnings and Revenues
by Zacks Equity Research
Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 75 cents per share in the first quarter of fiscal 2017.
McKesson (MCK) Beats on Earnings in Q3, Inks Buyout Deal
by Zacks Equity Research
McKesson Corporation (MCK) reported third-quarter fiscal 2017 earnings of $3.03 per share, beating the Zacks Consensus Estimate of $2.95 but declining from the year-ago figure of $3.18.
Stryker (SYK) Beats Q4 Earnings, Provides FY17 Guidance
by Zacks Equity Research
Maintaining its streak of positive earnings surprises, Stryker Corp (SYK) reported adjusted earnings of $1.78 per share in the fourth quarter of 2016, which comfortably beat the Zacks Consensus Estimate by 2 cents.
Cynosure (CYNO) Looks Good: Stock Adds 6.6% in Session
by Zacks Equity Research
Cynosure, Inc. (CYNO) shares rose over 6% in the last trading session.
Can Glaukos (GKOS) Stock Continue to Grow Earnings?
by Zacks Equity Research
Glaukos (GKOS) has a favorable Zacks Rank and is a fast-growing stock that is well positioned for future earnings growth.
Zacks.com featured highlights: Glaukos, Apogee Enterprises, Braskem SA, Sundance Energy Australia and Angang Steel
by Zacks Equity Research
Zacks.com featured highlights: Glaukos, Apogee Enterprises, Braskem SA, Sundance Energy Australia and Angang Steel
Becton, Dickinson Commercially Launches Precise WTA Kits
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis kits commercial available.
Baxter (BAX): Sluggish Macro Environment Mars Prospects
by Zacks Equity Research
On Jan 17, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.
Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals
Medidata Solutions Clinical Cloud Gets Picked by Celgene
by Zacks Equity Research
Medidata Solutions Inc. (MDSO) recently announced that Celgene Corporation adopted Medidata Clinical Cloud.
Pacific Biosciences (PACB) to Sell 10 PacBio Sequel Systems
by Zacks Equity Research
Pacific Biosciences of California, Inc. (PACB), announced that it will sell 10 PacBio Sequel Systems to Novogene Bioinformatics Technology Company, Ltd.
5 Stocks with Recent Price Strength to Boost Your Returns
by Zacks Equity Research
One should primarily target stocks that have recently been on a bullish run. Actually, stocks seeing price strength recently have a high chance of carrying the momentum forward.
Akers Biosciences (AKER) Closes Offering of 1.7M Shares
by Zacks Equity Research
Akers Biosciences, Inc. (AKER) recently announced the closing of a public offering of 1.7 million common shares.
4 Profitable Stocks with Amazingly High Returns
by Zacks Equity Research
Net income ratio gives us the exact profitability level of a company and reflects the percentage of net income to total sales revenue.
Intuitive Surgical (ISRG) Expects Strong Revenues in Q4
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) announced that it expects fourth-quarter 2016 revenues of approximately $757 million.
Fluidigm: Q4 Preliminary Results Fail to Cheer Investors
by Zacks Equity Research
The market is not really happy with South San Francisco, CA-based Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter and full-year 2016.